Iambic Therapeutics Files Initial S-1 for Nasdaq IPO
Iambic Therapeutics, Inc. (SEC file no. 0001997038) filed its initial S-1 registration statement on September 21, 2026 (57 MB). The biotech focuses on targeted protein degradation; all programs are preclinical or Phase I, with no approved products or revenue.
51CFO view：First-time biotech S-1 demands CFO expertise in R&D capitalization policy, clinical trial cost allocation, stock-based compensation modeling, and ‘cash runway’ disclosure under SEC Compliance & Disclosure Interpretations. Must justify non-GAAP metrics (e.g., cash burn per program) to underwriters and SEC staff.
Iambic Therapeutics, Inc. (SEC file no. 0001997038) filed its initial S-1 registration statement on September 21, 2026 (57 MB). The biotech focuses on targeted protein degradation; all programs are preclinical or Phase I, with no approved products or revenue.
Source：SEC EDGAR · S-1 招股书备案